Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
C Michael GibsonDanielle DuffySerge KorjianM Cecilia BahitGerald ChiJohn H AlexanderA Michael LincoffMark HeisePierluigi TricociLawrence I DeckelbaumSojaita Jenny MearsJose C NicolauRenato D LopesBela MerkelyBasil S LewisJan H CornelJaroslaw TrebaczAlexander ParkhomenkoPeter LibbyFrank M SacksThomas J PovsicMarc P BonacaShaun G GoodmanDeepak L BhattMichal TenderaPhillippe Gabriel StegPaul M RidkerPhilip AylwardJohn J P KasteleinChristoph BodeKenneth W MahaffeyStephen J NichollsStuart J PocockRoxana MehranRobert A Harringtonnull nullPublished in: The New England journal of medicine (2024)
Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.).
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- cardiovascular risk factors
- coronary artery disease
- st segment elevation myocardial infarction
- left ventricular
- st elevation myocardial infarction
- coronary artery bypass grafting
- atrial fibrillation
- acute coronary syndrome
- cardiovascular disease
- metabolic syndrome
- coronary artery bypass
- heart failure
- cardiovascular events
- phase iii
- clinical trial
- type diabetes
- aortic stenosis
- blood brain barrier
- open label